The objective is to provide terminally diagnosed patients with a last line of treatmentwhile improving overall quality of life. Tempol can be added to any chemotherapy regimento potentially reduce side effects and overcome chemoresistance.
The objective is to provide terminally diagnosed patients assigned to palliative care and
palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown
Tempol to work synergistically with a number of chemotherapy agents increasing treatment
response and reducing chemoresistance. Additionally, Tempol has been shown to provide
protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing
side effects. Tempol inhibits HIF-1/VEGF among others in cancerous cells while
upregulating GSH/NrF2 among others in non-cancerous cells.
Drug: Tempol
Tempol will be given as an adjunct to chemotherapy.
Other Name: MBM-0-1 MBM-02
Inclusion Criteria:
- metastatic terminally diagnosed cancer
Exclusion Criteria:
-
UCHealth University of Colorado Cancer Center - Anschutz Medical Campus
Aurora, Colorado, United States
Benji Crane
6264376506
bjcrane@matrixbiomed.com